ATE535529T1 - Verfahren zur acylierung von maytansinol mit chiralen aminosäuren - Google Patents

Verfahren zur acylierung von maytansinol mit chiralen aminosäuren

Info

Publication number
ATE535529T1
ATE535529T1 AT06800952T AT06800952T ATE535529T1 AT E535529 T1 ATE535529 T1 AT E535529T1 AT 06800952 T AT06800952 T AT 06800952T AT 06800952 T AT06800952 T AT 06800952T AT E535529 T1 ATE535529 T1 AT E535529T1
Authority
AT
Austria
Prior art keywords
maytansinol
acylation
amino acids
chiral amino
chiral
Prior art date
Application number
AT06800952T
Other languages
English (en)
Inventor
Guojie Ho
Darren Carrozzella
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE535529T1 publication Critical patent/ATE535529T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06800952T 2005-08-09 2006-08-08 Verfahren zur acylierung von maytansinol mit chiralen aminosäuren ATE535529T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70669405P 2005-08-09 2005-08-09
PCT/US2006/030857 WO2007021674A2 (en) 2005-08-09 2006-08-08 Method of acylating maytansinol with chiral amino acids

Publications (1)

Publication Number Publication Date
ATE535529T1 true ATE535529T1 (de) 2011-12-15

Family

ID=37758086

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06800952T ATE535529T1 (de) 2005-08-09 2006-08-08 Verfahren zur acylierung von maytansinol mit chiralen aminosäuren

Country Status (7)

Country Link
US (1) US7598375B2 (de)
EP (1) EP1913002B9 (de)
JP (1) JP5167130B2 (de)
AT (1) ATE535529T1 (de)
AU (1) AU2006280146B2 (de)
CA (1) CA2617953C (de)
WO (1) WO2007021674A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
DE60234094D1 (de) 2001-05-11 2009-12-03 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
CA2676244C (en) * 2007-01-25 2017-01-17 Kwok-Kin Wong Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
CN101688229B (zh) * 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
CL2008002083A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
CA2696360C (en) 2007-08-14 2018-11-20 Ludwig Institute For Cancer Research Monoclonal antibody targeting the egfr receptor and uses thereof
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
KR20120057565A (ko) 2009-04-01 2012-06-05 제넨테크, 인크. 항-FcRH5 항체 및 면역접합체 및 사용 방법
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
ES2544608T3 (es) * 2010-11-17 2015-09-02 Genentech, Inc. Conjugados de anticuerpo y de alaninil-maitansinol
KR20190089048A (ko) 2011-02-15 2019-07-29 이뮤노젠 아이엔씨 컨쥬게이트의 제조방법
SG10201605041VA (en) 2011-06-21 2016-08-30 Immunogen Inc Novel maytansinoid derivatives with peptide linker and conjugates thereof
CN104136461B (zh) 2011-09-22 2021-06-08 安姆根有限公司 Cd27l抗原结合蛋白
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
HUE055443T2 (hu) * 2012-09-26 2021-11-29 Immunogen Inc Javított eljárások maytansinol acilezéséhez
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Bcma抗原結合蛋白質
CN103254213B (zh) * 2012-12-21 2015-02-25 百奥泰生物科技(广州)有限公司 类美登素酯的制备方法及用于所述方法的组合物
CN103288957B (zh) 2012-12-21 2015-01-28 百奥泰生物科技(广州)有限公司 一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途
ES2728936T3 (es) 2013-01-25 2019-10-29 Amgen Inc Anticuerpos dirigidos contra CDH19 para melanoma
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
AU2014233385C1 (en) 2013-03-15 2019-09-19 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
CN110511279B (zh) 2013-05-30 2024-03-29 基尼克萨制药有限公司 制瘤素m受体抗原结合蛋白
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法
CN105585579A (zh) * 2014-10-24 2016-05-18 南京联宁生物制药有限公司 一种化合物及其制备方法以及美登素dm1的制备方法
CN104623687B (zh) * 2015-03-11 2017-09-05 中国科学院上海高等研究院 利用美登醇制备的抗体药物偶联物及其制备方法和应用
KR20170129769A (ko) 2015-03-17 2017-11-27 리제너론 파아마슈티컬스, 인크. 아미노산 아실화 시약 및 이의 사용 방법
KR20240142591A (ko) 2015-03-27 2024-09-30 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體3(fgfr3)之化合物的療法
PT3956332T (pt) 2019-04-18 2023-04-24 Indena Spa Processo diasterosselectivo para a preparação de ésteres de maitansinoides contendo tiol ou dissulfeto e seus intermediários
US20250382307A1 (en) * 2022-09-16 2025-12-18 Immunogen, Inc. Improved methods for preparing n-methyl alanine esters of maytansinol

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260609A (en) * 1977-06-01 1981-04-07 Merck & Co., Inc. Di- and tri- substituted thiazoles
JPS5566585A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) * 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
MXPA04008419A (es) * 2002-03-01 2004-11-26 Univ Tulane Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos.
US7301019B2 (en) * 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters

Also Published As

Publication number Publication date
EP1913002B9 (de) 2012-04-25
EP1913002A4 (de) 2010-10-27
JP5167130B2 (ja) 2013-03-21
CA2617953A1 (en) 2007-02-22
EP1913002A2 (de) 2008-04-23
JP2009504655A (ja) 2009-02-05
EP1913002B1 (de) 2011-11-30
AU2006280146A1 (en) 2007-02-22
US20070037972A1 (en) 2007-02-15
WO2007021674A3 (en) 2007-07-26
WO2007021674A2 (en) 2007-02-22
AU2006280146B2 (en) 2012-06-28
CA2617953C (en) 2013-12-17
US7598375B2 (en) 2009-10-06

Similar Documents

Publication Publication Date Title
ATE535529T1 (de) Verfahren zur acylierung von maytansinol mit chiralen aminosäuren
DE602005011656D1 (de) Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin
ATE475419T1 (de) Verfahren zur zubereitung von lansoprazol
DE602004032160D1 (de) Verfahren zur Zubereitung von Getränken
DE602004002519D1 (de) Verfahren zur Oberflächenbehandlung von Metallen
EP1912674B8 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
ATE464908T1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
DE602005016292D1 (de) Verfahren zur herstellung von glatiramer
EP1877175A4 (de) Vorrichtung und verfahren zur herstellung von radiopharmazeutika
ATE482966T1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
DE602004000313D1 (de) Verfahren zur Verfügungstellung von ozonenthaltendem Wasser
DE60325381D1 (de) Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität
DE602004020895D1 (de) Verfahren zur herstellung von kohlenstoffnanospulen
DE10390418D2 (de) Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
DE502004005626D1 (de) Verfahren zur herstellung von organoacylphosphiten
EP1899472A4 (de) Geänderter glyoxylat-shunt zur verbesserten produktion von aspartat abgeleiteter aminosäuren und chemikalien
DE60331111D1 (de) Verfahren zur Herstellung von martensitaushärtendem Stahl
EP1888106A4 (de) Zusammensetzungen und verfahren zur behandlung von ephrinsignalisierung mit cupredoxinen
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
ATA14432002A (de) Verbessertes verfahren zur singlet sauerstoff oxidation von organischen substraten
WO2005009361A3 (en) Method of treating hit patients with argatroban
ATE468032T1 (de) Verfahren zur verringerung von herbheit
DE602004002692D1 (de) Verfahren zur Herstellung von Topiramate
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung